Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design

Purpose of reviewHIV diversity is a major challenge to accurate detection of HIV-specific immunity in vitro and HIV vaccine immunogen design alike. Although achieving extensive coverage of global viral diversity is a common goal for both tasks, different strategies for achieving maximal in-vitro detection of responses and optimal in-vivo induction of immune responses may be needed. This review describes and compares some of the most recently developed approaches. Recent findingsSingle sequence-based antigen sets as well as polyvalent peptide test reagents have been developed over recent years that are suitable for detection of comprehensive CD4+ and CD8+ T-cell immunity in the naturally infected or vaccinated host. These tools permit increasingly accurate assessment of the host immune response, thus providing the basis for identification of immune correlates of controlled HIV infection. SummaryThese recent findings and newly developed strategies that allow more comprehensive detection of HIV-specific T-cell responses provide the tools necessary to assess vaccine immunogenicity and breadth within genetically different host populations and relative to diverse local viral populations. They will ultimately inform design of vaccine immunogen sequences that can induce broadly protective cellular immunity.

[1]  D. Nixon,et al.  HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides , 1988, Nature.

[2]  D. Nickle,et al.  Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope , 2005, Journal of Virology.

[3]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[4]  B. Walker,et al.  The challenges of host and viral diversity in HIV vaccine design. , 2006, Current opinion in immunology.

[5]  J. Mascola,et al.  Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.

[6]  Todd M. Allen,et al.  The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine Design , 2005, Journal of Virology.

[7]  S. Kent,et al.  Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. , 2005, Vaccine.

[8]  O. Yang,et al.  Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides. , 2005, Journal of immunological methods.

[9]  J. Sidney,et al.  Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV‐1 CTL epitope Gag77–85 , 2005, European journal of immunology.

[10]  Andrew K. Sewell,et al.  Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA , 2005, The Journal of experimental medicine.

[11]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[12]  Todd M. Allen,et al.  Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences , 2003, Journal of Virology.

[13]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[14]  F. M. Marincola,et al.  Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities , 2004, Journal of Virology.

[15]  James Theiler,et al.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.

[16]  David Heckerman,et al.  Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes , 2006, Nature Immunology.

[17]  Feng Gao,et al.  Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen , 2006, Journal of Virology.

[18]  A. Osterhaus,et al.  Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity. , 2005, The Journal of infectious diseases.

[19]  Alessandro Sette,et al.  Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1 1 , 2003, The Journal of Immunology.

[20]  Bette T. Korber,et al.  Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein , 2005, Journal of Virology.

[21]  Søren Brunak,et al.  Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation , 2002, Journal of Virology.

[22]  J. Kaplan,et al.  Solid-Phase Epitope Recovery: A High Throughput Method for Antigen Identification and Epitope Optimization , 2002, The Journal of Immunology.

[23]  Z. Weng,et al.  Ancestral and consensus envelope immunogens for HIV-1 subtype C. , 2006, Virology.

[24]  C. Katlama,et al.  Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. , 1996, Journal of immunology.

[25]  B. Autran,et al.  AIDS virus-specific cytotoxic T lymphocytes in lung disorders , 1987, Nature.

[26]  Feng Gao,et al.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. , 2006, Virology.

[27]  C. Williamson,et al.  Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. , 2006, The Journal of general virology.

[28]  Galit Alter,et al.  De Novo Generation of Escape Variant-Specific CD8+ T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection , 2005, Journal of Virology.

[29]  R. Shankarappa,et al.  Minimization of genetic distances by the consensus, ancestral, and center-of-tree (COT) sequences for HIV-1 variants within an infected individual and the design of reagents to test immune reactivity. , 2006, Virology.

[30]  Sarah Rowland-Jones,et al.  Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.

[31]  L. Jagodzinski,et al.  HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides , 2005, AIDS.

[32]  D. Nickle,et al.  Consensus and Ancestral State HIV Vaccines , 2003, Science.

[33]  Feng Gao,et al.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. , 2007, Virology.

[34]  Peter B Gilbert,et al.  Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. , 2006, Vaccine.